News
Videos
Conferences
Events
Resources
Subscribe

Opinion|Videos|May 15, 2024

Overview of Efficacy and Safety Data for Current CLL Treatment Options

A general overview of efficacy and safety data for current treatment options for patients with chronic lymphocytic leukemia.

Episodes in this series

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 1 Understanding a CLL Diagnosis

Yuliya P.L Linhares, MD, an expert on CLL

EP. 2 Diagnostic Tests in CLL

Video 3 - "Goals of Treatment for Patients With CLL"

EP. 3 Goals of Treatment for Patients With CLL

Video 4 - "Current First-Line Treatment Options in CLL"

EP. 4 Current First-Line Treatment Options in CLL

Yuliya P.L Linhares, MD, an expert on CLL

EP. 5 Factors That Guide CLL Treatment Decisions

Josie Montegaard, MSN, AGPCNP-BC, an expert on CLL

EP. 6 What to Expect from Treatment

Video 7 - "Overview of Efficacy and Safety Data for Current CLL Treatment Options"

EP. 7 Overview of Efficacy and Safety Data for Current CLL Treatment Options

Video 8 - "Acalabrutinib-Based Treatment Clinical Trial Updates"

EP. 8 Acalabrutinib-Based Treatment Clinical Trial Updates

Yuliya P.L Linhares, MD, an expert on CLL

EP. 9 Venetoclax-Based Treatment Clinical Trial Updates

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 10 Zanubrutinib-Based Treatment Clinical Trial Updates

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 11 Ibrutinib-Based Treatment Clinical Trial Updates

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 12 Newer Combinations for the Treatment of CLL

Josie Montegaard, MSN, AGPCNP-BC, an expert on CLL

EP. 13 What to Know Before Starting Your CLL Treatment

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 14 An Overview of Potential Treatment Adverse Effects

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 15 Treatment Decisions in R/R CLL

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 16 Shared Decision-Making and Supportive Care in the CLL Treatment Journey

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 17 Optimizing Overall Health During CLL Management

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 18 Getting the Most From Your CLL Care Team

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Jaypirca therapy improved progression-free survival versus bendamustine plus Rituxan a phase 3 trial for untreated CLL/SLL: © stock.adobe.com.

Jaypirca Significantly Improves PFS Outcomes in Untreated CLL/SLL

BySabrina Serani

December 9th 2025

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

ByJason Broderick

December 8th 2025

CLL

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

ByJason M Broderick

December 7th 2025

fda approved

FDA Approves Jaypirca for Relapsed/Refractory CLL or SLL

December 3rd 2025

Addressing Common Talquetamab Misunderstandings

BySamantha Shenoy, MSN, NP,Alan Plisskin,Mary Kay Yamamoto

November 24th 2025

Trending on CURE

FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer

Acupuncture Improves Cognitive Function in Breast Cancer Survivors

Light the Night and Survivorship: The Importance of Remembrance

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

Accepting That You Are Changed by Cancer

© 2025 MJH Life Sciences^®

All rights reserved.